EMAV members at the meeting on 03rd/04th of March in Brussels
EMAV Workshop and General Assembly in Brussels
With the admittance of Brabants Veterinair Laboratium EMAV is representing 19 members from 10 European countries yet. Moniek Verhagen and Maarten van den Berg took the opportunity to present the activities of the lab and the background of the use of autogenous vaccines in the Netherlands. Carlos Artigas, Managing Director of EMAV member Calier, impressed the membership with his view on the Spanish circumstances.
Gerfried Zeller, Managing Director of EMAV, reported about the comprehensive network activities of the association. So EMAV is not only established as stakeholder with EMA (European Medicines Agency) and HMA (Heads of Medicines Agencies) but build up close relationships with representatives of the Vet professionals, like FVA and UEVP, as well as with Animalhealth Europe and other representatives on national and European level too.
In the focus of the Workshop discussions were a draft of dedicated GMP rules for autogenous vaccines in execution of regulation (EU) 2019/6, prepared by the EMAV Scientific Working Group. Basic findings of this evaluation will be presented at the scientific conference about “Autogenous Vaccines: Quality of production and movement in a common market” in September in Munich, who will be organised from EMAV and IABS (International Alliance for Biological Standardization) in cooperation with the Ludwig Maximilian University. The conference will focus on how to introduce harmonised regulations for the future availability of autogenous vaccines within Europe. Autogenous veterinary vaccines are increasingly used to address critical vaccination needs whenever conventionally-authorised vaccines are not available, stated Klaus-Peter Behr, Chair of EMAV. The use of these vaccines in livestock, aquaculture and companion animals should be harmonised concerning the quality of production, testing, use or surveillance involving these novel products exists throughout Europe.